The lung transplant nurse’s communication challenge
Lung transplant nursing spans a longer arc than almost any other specialty in clinical care. The relationship between the transplant clinic nurse and the patient who receives a bilateral lung transplant for end-stage interstitial pulmonary fibrosis or emphysema begins months before the surgery, extends through the perioperative period and its acute complications, and continues for years into the post-transplant surveillance that is required for the life of the allograft. At each phase of this arc, the nurse encounters a predictable and structurally different communication failure with Spanish-speaking patients: a failure of sequence (the patient does not understand that listing and evaluation are parallel, not sequential), a failure of mechanism (the patient does not understand why the transplanted lungs feel worse rather than better in the first three days), and a failure of biology (the patient does not understand why perfectly adherent immunosuppression does not prevent the progressive airflow decline of chronic lung allograft dysfunction).
The structural feature that unites all three misunderstandings is the same: the patient’s model of lung transplant is coherent and internally consistent but is based on incomplete information. The patient who believes the transplant evaluation must conclude before the waitlist begins is drawing a reasonable inference from how most medical processes work — complete a test before starting treatment. The patient who believes that feeling worse three days after bilateral lung transplant means something went wrong is drawing a reasonable inference from every prior medical experience she has had — procedures that went well produce immediate improvement, not worsening. The patient whose spirometry shows a 25 percent FEV1 decline after two and a half years of perfect immunosuppression adherence and no bronchoscopy-confirmed rejection is drawing a reasonable inference from what he was told immunosuppression does — prevent rejection, therefore preserve lung function. Each inference is wrong in a specific and explainable way. The lung transplant nurse who can deliver that explanation in accurate, accessible Spanish is the person who keeps patients adherent, emotionally engaged, and prepared to act appropriately at each stage of a pathway that asks a great deal of them over a very long time.
Three conversations that recur with Spanish-speaking patients across the lung transplant pathway:
Scenario 1: Juan Morales — 62, retired landscaper from Houston, end-stage IPF, transplant evaluation clinic visit 3
Juan Morales is sixty-two years old, a retired commercial landscaper who spent thirty-five years maintaining grounds for office parks, apartment complexes, and hotel properties across the greater Houston metropolitan area. He retired at fifty-nine after noticing progressive exertional dyspnea that he initially attributed to the Texas summer heat. His primary care physician ordered pulmonary function testing; the results showed a restrictive pattern with an FVC of 68 percent predicted and a DLCO of 52 percent predicted. High-resolution CT of the chest showed bilateral basal predominant honeycombing with traction bronchiectasis and minimal ground-glass opacification — the usual interstitial pneumonia pattern. Surgical lung biopsy confirmed usual interstitial pneumonia histopathology. Diagnosis: idiopathic pulmonary fibrosis.
Juan was started on nintedanib, an antifibrotic agent shown in the INPULSIS trials to slow the rate of FVC decline in IPF. Over the subsequent three years, his disease progressed despite medication. At the time of referral to the lung transplant program, his pulmonary function had declined to an FVC of 48 percent predicted and a DLCO of 32 percent predicted. He required 4 liters of supplemental oxygen continuously at rest, with desaturation to 84 percent on minimal exertion. His 6-minute walk test distance was 140 meters, stopping at four minutes due to oxygen desaturation and lower-extremity fatigue. Body mass index: 17.8. Serum albumin: 2.8 grams per deciliter. He was referred to the transplant program by his pulmonologist with a note documenting “progressive IPF, oxygen-dependent at rest, no further antifibrotic options.”
At his third evaluation clinic visit — the visit in which the nurse coordinator reviewed the evaluation timeline — Juan arrived with his wife Esperanza, a former teacher’s aide who had been managing his supplemental oxygen equipment and appointment logistics since his condition had made driving impossible. Juan sat in the examination chair with his oxygen concentrator tubing visible and the familiar posture of a man who calibrated every movement to minimize the dyspnea the smallest exertion triggered. He had been polite at every prior visit and had completed the paperwork and testing asked of him without complaint. But at this visit, something had changed.
“Llevo tres meses viniendo aquí,” he said, without preamble, to lung transplant coordinator Gabriela Santos-Fuentes as she entered the room. “Tres meses de pruebas, de rehabilitación, de análisis de sangre. Me dicen que el proceso puede durar seis meses más. Seis meses. Mis pulmones están peor que cuando llegué. Puedo sentirlo. ¿Cuándo me ponen en la lista?” (I have been coming here for three months. Three months of tests, rehabilitation, blood work. They tell me the process can take six more months. Six months. My lungs are worse than when I arrived. I can feel it. When do they put me on the list?)
Esperanza added: “Cada semana que pasa, está más corto de aliento. ¿La lista de espera no empieza hasta que terminen todas las pruebas?” (Every week that passes, he is more short of breath. Does the waitlist not start until all the tests are finished?)
Gabriela recognized the misunderstanding immediately. It was the most common structural error that patients and families made about the evaluation timeline, and it was entirely understandable: the evaluation and the waitlist felt, from the patient’s vantage point, like a sequential process in which every step of evaluation had to be completed before the name went on a list. The emotional consequence of this model was that every week of evaluation felt like a week of lost position on a list that did not yet exist for Juan — a list that was accumulating while he was deteriorating.
“Quiero explicarle algo importante sobre cómo funciona la lista de espera,” Gabriela said, “porque creo que hay una parte del proceso que no hemos explicado bien.” (I want to explain something important about how the waitlist works, because I think there is a part of the process that we have not explained well.)
She started with the fundamental correction. The waitlist and the evaluation were not sequential — they were parallel. The Lung Allocation Score was a numerical formula calculated from Juan’s clinical data: his diagnosis of IPF, his FVC of 48 percent predicted, his 6-minute walk test distance of 140 meters, his oxygen requirement, his pulmonary artery pressure from the echocardiogram, his serum creatinine. That calculation was updated continuously in the UNOS database as new clinical data came in. The LAS score determined Juan’s position relative to other patients in his blood group and geographic region. His LAS, based on his current clinical picture, was approximately 43 — a number that placed him in the upper third of the active waitlist for bilateral lung transplant in the South Central UNOS region.
“Su nombre ya está en el proceso de estar en la lista,” she said. “El puntaje que determina su posición en la lista — el Lung Allocation Score — ya existe y ya refleja lo grave que está su situación. No es algo que se calcula al final de la evaluación — se calcula ahora, con los datos que ya tenemos, y se actualiza cada vez que hay datos nuevos.” (Your name is already in the process of being on the list. The score that determines your position on the list — the Lung Allocation Score — already exists and already reflects how serious your situation is. It is not something calculated at the end of the evaluation — it is calculated now, with the data we already have, and updated every time there is new data.)
Juan looked at Esperanza. “¿Entonces ya estoy en la lista?” (So I am already on the list?)
“Oficialmente la inscripción en la lista requiere que el equipo de trasplante apruebe su caso en el comité, y eso está previsto para las próximas semanas,” Gabriela said. “Pero el puntaje que determina su posición ya existe y ya incluye sus datos actuales. La evaluación no lo está alejando de la lista — está ocurriendo al mismo tiempo que la lista se forma.” (Officially the enrollment on the list requires the transplant team to approve your case in committee, and that is scheduled for the next few weeks. But the score that determines your position already exists and already includes your current data. The evaluation is not keeping you away from the list — it is happening at the same time the list is forming.)
She turned to the harder question: why the rehabilitation and nutritional assessment mattered. She was direct about Juan’s specific numbers. His 6-minute walk test at 140 meters was a clinical risk signal, not a bureaucratic threshold. Patients who walked fewer than 150 meters before lung transplant had significantly higher rates of primary graft dysfunction, prolonged mechanical ventilation, and 90-day post-transplant mortality compared with patients who walked 250 meters or more. This was not a rule that the transplant program had invented — it was a finding from outcome studies that had been replicated across programs and that the team used to counsel patients about surgical risk. The pulmonary rehabilitation program was the specific intervention designed to address it: eight weeks of supervised exercise conditioning, breathing retraining, and functional capacity building that had been shown in pre-transplant rehabilitation trials to increase 6-minute walk test distance by 40 to 80 meters in patients with end-stage lung disease.
“Su test de caminata fue 140 metros,” she said. “Los estudios muestran que los pacientes que caminan menos de 150 metros antes del trasplante tienen más complicaciones después de la cirugía que los que caminan más. La rehabilitación pulmonar que está haciendo tiene el objetivo específico de mejorar esa cifra. Eso no es un retraso al trasplante — es la preparación que mejora sus probabilidades de sobrevivir la cirugía cuando llegue el pulmón.” (Your walk test was 140 meters. Studies show that patients who walk less than 150 meters before transplant have more complications after surgery than those who walk more. The pulmonary rehabilitation you are doing has the specific goal of improving that number. That is not a delay to transplant — it is the preparation that improves your chances of surviving the surgery when the lung arrives.)
Esperanza asked: “¿Y la nutrición? Su peso ha bajado mucho este año.” (And the nutrition? His weight has dropped a lot this year.)
Gabriela explained the albumin and BMI findings. Juan’s albumin of 2.8 and BMI of 17.8 were independent predictors of primary graft dysfunction and impaired anastomotic healing after the bronchial anastomosis. The bronchial anastomosis — the surgical connection between the transplanted bronchus and the recipient’s own airway — was the most technically demanding aspect of the surgery and the suture line most vulnerable to poor healing. Malnutrition impaired the regenerative capacity of the bronchial epithelium at the anastomotic site and increased the risk of dehiscence and stenosis. The nutritional program running in parallel with rehabilitation was not a cosmetic intervention — it was addressing a specific surgical risk factor.
“La desnutrición que tiene ahora aumenta el riesgo de complicaciones en la anastomosis broncal — el punto donde el bronquio del donante se conecta al suyo — después de la cirugía,” Gabriela said. “El programa nutricional está dirigido a esa complicación específica. No es un paso adicional por requisito — es porque hay datos que muestran que los pacientes que mejoran su estado nutricional antes del trasplante tienen mejores resultados después.” (The malnutrition you have now increases the risk of complications at the bronchial anastomosis — the point where the donor bronchus connects to yours — after surgery. The nutritional program is directed at that specific complication. It is not an additional step for requirement purposes — it is because there is data showing that patients who improve their nutritional status before transplant have better outcomes afterward.)
Juan was quiet. “¿Entonces lo que me están pidiendo en la rehabilitación y en la nutrición no es para poner mi nombre en la lista — es para que cuando llegue el pulmón, yo pueda sobrevivir la cirugía?” (So what you are asking me in rehabilitation and nutrition is not to put my name on the list — it is so that when the lung arrives, I can survive the surgery?)
“Exactamente,” Gabriela said. “Las dos cosas están ocurriendo al mismo tiempo: la lista se está formando con su puntaje actual, y la rehabilitación y la nutrición están mejorando las condiciones con las que va a entrar a esa cirugía. Un pulmón puede llegar en tres meses o en diez — no sabemos cuándo. Lo que sí sabemos es que cuando llegue, queremos que usted esté en las mejores condiciones posibles.” (Exactly. Both things are happening at the same time: the list is forming with your current score, and the rehabilitation and nutrition are improving the conditions with which you will enter that surgery. A lung can arrive in three months or in ten — we do not know when. What we do know is that when it arrives, we want you to be in the best possible condition.)
Juan looked at his oxygen tubing for a moment. “Entonces la rehabilitación y yo estamos compitiendo para ver quién mejora más rápido,” he said quietly. (So the rehabilitation and I are competing to see who improves faster.)
Gabriela smiled. “Así es exactamente cómo lo vería yo,” she said. “Usted compitiendo con su enfermedad. La rehabilitación de su parte.” (That is exactly how I would see it. You competing with your disease. The rehabilitation on your side.)
Juan agreed to continue rehabilitation and accepted a referral to the transplant program’s nutritional support team for a structured pre-transplant nutritional protocol with target goals at 4 and 8 weeks.
Scenario 2: Maria Elena Ortiz-Vargas — 57, retired teacher from Miami, end-stage COPD, bilateral lung transplant day 3
Maria Elena Ortiz-Vargas is fifty-seven years old, a retired elementary school teacher who spent twenty-nine years teaching third and fourth grade in Miami-Dade County public schools. She was diagnosed with COPD at age forty-nine when spirometry ordered after a respiratory hospitalization showed an FEV1 of 52 percent predicted with a post-bronchodilator FEV1 of 58 percent predicted and a significant smoking history. She stopped smoking immediately after diagnosis and was treated with long-acting bronchodilators and pulmonary rehabilitation. Despite optimal management, her COPD progressed, classified as GOLD Stage IV emphysema-predominant disease with FEV1 of 20 percent predicted at referral, hyperinflation (TLC 145 percent predicted), and severe diffusion impairment (DLCO 25 percent predicted). She required 6 liters of continuous supplemental oxygen at home, could not ambulate more than twenty feet without oxygen desaturation, and had been hospitalized four times in the prior year for acute exacerbations.
Maria Elena underwent bilateral lung transplant via bilateral sequential thoracotomy. The surgery lasted eight hours. Left donor lung cold ischemia time: 6 hours 43 minutes. Right donor lung cold ischemia time: 7 hours 21 minutes. Both bronchial anastomoses were technically satisfactory. She was extubated in the ICU on post-operative day one and transferred to the lung transplant step-down unit on post-operative day two. At that point, her oxygen requirement via Venturi mask was 10 liters per minute to maintain SpO2 of 92 to 94 percent. Her chest X-ray showed bilateral patchy airspace opacities, predominant in the lower lobes.
On post-operative day three, Maria Elena was awake, alert, and visibly distressed. Her daughter Valentina, a thirty-one-year-old nursing assistant who had taken a leave of absence from her job to be present through the transplant, sat beside her. Maria Elena was wearing a non-rebreather mask at 10 liters per minute. She had been told before the transplant that she would likely be on lower oxygen by day three than she had needed at home.
“Antes de la cirugía necesitaba seis litros,” Maria Elena said to lung transplant nurse David Chen-Rodriguez, as he came in for the morning assessment. “Ahora necesito diez. Me dijeron que iba a mejorar. ¿Por qué estoy peor? ¿Mi cuerpo rechazó los pulmones?” (Before the surgery I needed six liters. Now I need ten. They told me I was going to improve. Why am I worse? Did my body reject the lungs?)
Valentina added quickly: “Cuando la veo así me preocupo que algo salió mal que no nos están diciendo.” (When I see her like this I worry that something went wrong that they are not telling us.)
David understood the full weight of the moment. Maria Elena had spent years deteriorating on supplemental oxygen, had undergone a major bilateral thoracic surgery, and now on day three was requiring more supplemental oxygen than before the surgery, with a chest X-ray showing infiltrates in the new lungs she had waited years to receive. The gap between the expected outcome and the experienced reality was complete. The explanation had to be precise, not reassuring, because false reassurance in this moment would dissolve the moment her oxygen requirement did not improve on the schedule she was told to expect.
“Señora Ortiz, lo que está pasando en sus pulmones tiene un nombre específico y quiero explicarle qué es, porque no es rechazo,” David said. “Se llama disfunción primaria del injerto — en inglés, primary graft dysfunction — y es diferente del rechazo en el mecanismo, en el tiempo en que ocurre, y en el tratamiento.” (Mrs. Ortiz, what is happening in your lungs has a specific name and I want to explain to you what it is, because it is not rejection. It is called primary graft dysfunction — in English, primary graft dysfunction — and it is different from rejection in the mechanism, in the timing in which it occurs, and in the treatment.)
He explained the mechanism. During the surgery, the donor lungs spent time outside a living body — they were procured from the donor, preserved in cold solution, and transported to the operating room. The right lung had a cold ischemia time of seven hours and twenty-one minutes. During that period, the cellular metabolism of the donor lung tissue was slowed by hypothermia but not eliminated — cells were consuming oxygen and producing metabolic byproducts without the normal circulation to clear them. When the surgeon released the vascular clamps and allowed Maria Elena’s blood to flow into the transplanted lungs, the sudden return of warm, oxygen-rich blood to cold, metabolically stressed tissue triggered an inflammatory cascade. Reactive oxygen species were produced in large quantities as oxygen returned to cells that had been anoxic. Neutrophils — inflammatory white blood cells — migrated into the alveolar tissue in response to the cytokine signals. The result was alveolar inflammation and increased permeability: fluid leaking into the alveolar spaces and bronchioles, producing the infiltrates on the chest X-ray and the impaired gas exchange that was increasing Maria Elena’s oxygen requirement.
“Este proceso — el retorno de la sangre a los tejidos que estuvieron sin circulación — se llama lesión por isquemia-reperfusión,” David said. “Es similar a lo que ocurre cuando se libera un torniquete de un brazo después de una cirugía: el retorno de la sangre produce una reacción inflamatoria en los tejidos. En los pulmones, esa reacción hace que los alveolos — las bolsitas donde se produce el intercambio de oxígeno — se llenen parcialmente de líquido. Por eso la radiografía de tórax muestra infiltrados. Por eso necesita más oxígeno que antes de la cirugía. No porque los pulmones estén siendo rechazados, sino porque esa reacción inflamatoria está ocurriendo mientras los pulmones se adaptan.” (This process — the return of blood to tissues that were without circulation — is called ischemia-reperfusion injury. It is similar to what happens when you release a tourniquet from an arm after surgery: the return of blood produces an inflammatory reaction in the tissues. In the lungs, that reaction causes the alveoli — the little sacs where oxygen exchange occurs — to partially fill with fluid. That is why the chest X-ray shows infiltrates. That is why you need more oxygen than before surgery. Not because the lungs are being rejected, but because that inflammatory reaction is occurring while the lungs adapt.)
Valentina asked: “¿Y cómo se trata?” (And how is it treated?)
“El tratamiento es de soporte: le damos el oxígeno que necesita mientras los pulmones se recuperan solos,” David said. “Esta reacción inflamatoria se produce en su punto máximo entre las 48 y 72 horas después de que la sangre regresó a los pulmones — que fue el momento de la cirugía. El día dos después de la cirugía fue ayer. Lo que esperamos es que en los próximos dos a tres días, la inflamación disminuya y los alveolos se limpien, y el oxígeno que necesita baje.” (The treatment is supportive: we give you the oxygen you need while the lungs recover on their own. This inflammatory reaction reaches its peak between 48 and 72 hours after the blood returned to the lungs — which was the moment of surgery. Day two after surgery was yesterday. What we expect is that over the next two to three days, the inflammation will decrease and the alveoli will clear, and the oxygen you need will decrease.)
Maria Elena looked at the monitor. “¿Cómo saben que está mejorando y no empeorando?” (How do you know it is improving and not worsening?)
David pointed to the morning arterial blood gas result on the chart. “Hay un número que usamos para seguir cómo están funcionando los pulmones: el ratio PaO2/FiO2 — la relación entre el oxígeno en su sangre y el oxígeno que le estamos dando,” he said. “Ayer por la tarde ese número era 156. Esta mañana es 198. Cuando ese número sube, los pulmones están transfiriendo el oxígeno mejor. El oxígeno que necesita al paó puede haber subido — porque ajustamos para mantener su saturación estable. Pero la eficiencia de los pulmones está mejorando.” (There is a number we use to follow how the lungs are functioning: the PaO2/FiO2 ratio — the relationship between the oxygen in your blood and the oxygen we are giving you. Yesterday afternoon that number was 156. This morning it is 198. When that number rises, the lungs are transferring oxygen better. The oxygen you need externally may have risen — because we adjust to keep your saturation stable. But the efficiency of the lungs is improving.)
“¿Y el rechazo cómo se diferencia de esto?” Valentina asked. (And how does rejection differ from this?)
David explained the distinction clearly. Acute cellular rejection was a different immunological mechanism — it involved the immune system recognizing donor HLA antigens on the transplanted bronchial epithelium and vascular endothelium and mounting a cytotoxic T-cell response against those cells. Rejection had a different time course: it typically did not begin until at least day 5 post-transplant and more commonly presented in the weeks to months following surgery, when the initial immunosuppression was established and any primary graft dysfunction had resolved. Rejection was diagnosed by transbronchial biopsy showing perivascular and submucosal lymphocytic infiltrates — a very different histological picture from the alveolar inflammation of ischemia-reperfusion injury. And rejection had a different treatment: high-dose pulse methylprednisolone intravenously for three days.
“Lo que tiene ahora y el rechazo son dos procesos diferentes en el mecanismo, en el tiempo en que ocurren, y en cómo se diagnostican y tratan,” David summarized. “Lo que tiene ahora ocurre en las primeras 72 horas. El rechazo celular agudo, si ocurre, empieza después del día 5. Para entonces, lo que tiene ahora debería estar resuelto. Estaría viendo una mejora en su saturación y en el oxígeno externo que necesita. Si en cambio eso no mejora o empieza a empeorar en los próximos días, realizamos una broncoscopía con biopsia para buscar rechazo. Pero lo que estamos viendo ahora es la trayectoria esperada de recuperación de disfunción primaria del injerto.” (What you have now and rejection are two different processes in mechanism, in the timing in which they occur, and in how they are diagnosed and treated. What you have now occurs in the first 72 hours. Acute cellular rejection, if it occurs, starts after day 5. By then, what you have now should be resolved. You would be seeing improvement in your saturation and in the external oxygen you need. If instead that does not improve or starts to worsen in the next few days, we perform a bronchoscopy with biopsy to look for rejection. But what we are seeing now is the expected recovery trajectory of primary graft dysfunction.)
Maria Elena was quiet. Then: “Entonces los pulmones no están siendo rechazados. Están recuperándose de algo distinto.” (So the lungs are not being rejected. They are recovering from something different.)
“Exactamente,” David said. “Y están mejorando. El número que revisamos esta mañana lo muestra.” (Exactly. And they are improving. The number we checked this morning shows it.)
Valentina exhaled. She asked David to explain the number again slowly so she could write it down and watch it herself. He did.
Scenario 3: Carlos Mendoza-Ríos — 53, retired bus driver from San Antonio, 2.5 years post bilateral lung transplant for IPF
Carlos Mendoza-Ríos is fifty-three years old, a retired metropolitan bus driver who spent twenty-seven years on the same San Antonio routes before being forced to retire at fifty when his diagnosis of IPF made sustained physical work impossible. He underwent bilateral lung transplant at age fifty, receiving lungs from a 38-year-old donor. The immediate post-operative course was uncomplicated: mild primary graft dysfunction Grade 1 that resolved by post-operative day 3, no bronchial anastomosis complications. He was discharged on post-operative day eleven on standard triple immunosuppression: tacrolimus targeting a trough of 10 to 12 nanograms per milliliter in the first year, mycophenolate mofetil 750 milligrams twice daily, and prednisone 5 milligrams daily.
Carlos was an adherent patient. He attended every clinic appointment. He tested his tacrolimus levels on schedule. At every annual bronchoscopy, transbronchial biopsies showed no evidence of acute cellular rejection — Banff Grade A0 at 6 months, 12 months, and 18 months. His pulmonary function had recovered to what both he and the team considered an excellent result: FEV1 of 2.9 liters at 12 months (83 percent predicted), FEV1 of 2.8 liters at 18 months (80 percent predicted). He had walked five kilometers a day without supplemental oxygen — something he had not done in five years before transplant. He had returned to occasional volunteering as a driving instructor at a local community college, something his IPF had forced him to give up.
At his 30-month routine clinic visit, his spirometry was repeated. FEV1: 2.1 liters — 60 percent predicted. The FVC was 3.4 liters, essentially unchanged from 18 months. The FEV1 to FVC ratio had fallen from 0.78 at 18 months to 0.62. The pattern was obstructive — a progressive decline in airflow with preservation of total lung volume. He had not been hospitalized. He had no symptoms he could identify as different from his baseline: mild dyspnea with heavy exertion, which he had attributed to normal deconditioning. He had not noticed the decline in his functional capacity because it had been gradual.
Lung transplant clinic nurse Patricia Varela-Cruz reviewed the spirometry results with Carlos and his sister Rosa, who had accompanied him to this appointment as she often did. Carlos sat across from her with the spirometry printout on the desk between them, looking at the numbers with the careful attention of a man who had been tracking his own measurements for two and a half years.
“Estos números no me cuadran,” Carlos said. “El FEV1 era 2.8 hace un año. Ahora es 2.1. Eso es una caída grande. Pero yo tomo el tacrolimus todos los días a la misma hora. Mi nivel siempre está entre 8 y 10. La última broncoscopía no mostró rechazo. ¿Cómo puede haber una caída así si no hay rechazo?” (These numbers do not add up to me. The FEV1 was 2.8 a year ago. Now it is 2.1. That is a large drop. But I take tacrolimus every day at the same time. My level is always between 8 and 10. The last bronchoscopy showed no rejection. How can there be a drop like this if there is no rejection?)
Rosa said: “¿Estaría pasando algo que no se ve en la biopsia?” (Could something be happening that does not show on the biopsy?)
Patricia recognized the precision of both questions. Carlos was not confused — he was applying his two and a half years of accurate understanding of the transplant process to a new clinical event that fell outside his model. His model was: tacrolimus prevents rejection, rejection damages the lung, I have taken my tacrolimus and had no rejection, therefore my lung should not be damaged. The model was correct in its individual components and wrong in its conclusion because it did not account for a mechanism of allograft injury that tacrolimus was not designed to address.
“Quiero explicarle cómo está funcionando su tacrolimus, porque lo que le voy a decir depende de entender eso primero,” Patricia said. “El tacrolimus funciona bloqueando una señal específica en los linfocitos T — la señal que los activa para atacar. Eso es exactamente lo que ha estado haciendo bien durante dos años y medio. Las biopsias lo confirman: no ha habido rechazo celular agudo. El tacrolimus está haciendo su trabajo.” (I want to explain how your tacrolimus is working, because what I am going to tell you depends on understanding that first. Tacrolimus works by blocking a specific signal in T lymphocytes — the signal that activates them to attack. That is exactly what it has been doing well for two and a half years. The biopsies confirm it: there has been no acute cellular rejection. Tacrolimus is doing its job.)
She paused. “Lo que está ocurriendo en sus pulmones ahora no es rechazo celular agudo. Es un proceso diferente — un proceso que afecta a los bronquiolos pequeños dentro del pulmón, que el tacrolimus no está diseñado para prevenir porque ese proceso no pasa por la misma señal que el tacrolimus bloquea.” (What is happening in your lungs now is not acute cellular rejection. It is a different process — a process that affects the small bronchioles inside the lung, which tacrolimus is not designed to prevent because that process does not go through the same signal that tacrolimus blocks.)
She explained the biology of bronchiolitis obliterans syndrome. In BOS, the small airways — the bronchioles that were 1 to 2 millimeters in diameter and conducted air to the alveolar units where gas exchange occurred — underwent a progressive fibroproliferative process: the lining of the bronchiole was injured by chronic alloimmune stimulation at a subclinical level; injured bronchiolar epithelial cells underwent epithelial-mesenchymal transition, transforming into myofibroblasts; myofibroblasts produced collagen and extracellular matrix proteins; the granulation tissue that formed in the bronchiolar lumen matured into dense fibrotic scar; the scar narrowed the bronchiolar airway; and the spirometric consequence was exactly what Carlos’s data showed — FEV1 declining because small airway obstruction impaired expiratory flow, while FVC was preserved because total lung volume was not restricted by the fibrotic process in the small airways.
“El proceso que está ocurriendo en los bronquiolos pequeños de su pulmón se llama disfunción crónica del aloinjerto — o CLAD en inglés — en su tipo obstructivo, que se llama síndrome de bronquiolitis obliterante,” Patricia said. “Los bronquiolos se van obstruyendo con tejido cicatricial. La obstrucción dificulta el flujo de aire al exhalar, que es lo que mide el FEV1. Pero la capacidad total del pulmón — el FVC — no ha cambiado, porque la cicatriz en los bronquiolos no restringe la cantidad total de aire que puede entrar al pulmón. Por eso el FEV1 bajó y el FVC no — eso es el patrón obstructivo que explica exactamente lo que su espirometría está mostrando.” (The process occurring in the small bronchioles of your lung is called chronic lung allograft dysfunction — or CLAD in English — in its obstructive type, which is called bronchiolitis obliterans syndrome. The bronchioles are progressively blocked with scar tissue. The obstruction makes it difficult for air to flow when exhaling, which is what FEV1 measures. But the total lung capacity — the FVC — has not changed, because the scar in the bronchioles does not restrict the total amount of air that can enter the lung. That is why FEV1 dropped and FVC did not — that is the obstructive pattern that explains exactly what your spirometry is showing.)
Carlos tapped the printout. “¿Y el tacrolimus no lo puede prevenir porque es un proceso diferente?” (And tacrolimus cannot prevent it because it is a different process?)
“Exactamente,” Patricia said. “El tacrolimus previene el rechazo celular agudo bloqueando la calcineurina en los linfocitos T. El proceso que está afectando los bronquiolos — la fibroproliferación, la transición epitelial a miofibroblasto, la producción de colágeno — ocurre por una cascada diferente que el tacrolimus no toca. Usted ha hecho todo bien. El tacrolimus hizo lo que debía hacer. Este proceso ocurre en aproximadamente la mitad de los pacientes de trasplante pulmonar a los cinco años — no es una falla del medicamento ni de su adherencia. Es el obstáculo más frecuente en el largo plazo después del trasplante pulmonar.” (Exactly. Tacrolimus prevents acute cellular rejection by blocking calcineurin in T lymphocytes. The process affecting the bronchioles — fibroproliferation, epithelial to myofibroblast transition, collagen production — occurs through a different cascade that tacrolimus does not touch. You have done everything right. Tacrolimus did what it was supposed to do. This process occurs in approximately half of lung transplant patients at five years — it is not a failure of the medication or of your adherence. It is the most frequent long-term obstacle after lung transplant.)
Rosa asked: “¿Qué se puede hacer?” (What can be done?)
Patricia explained the treatment approach. The management of BOS/CLAD had two phases. First, augmentation of the existing immunosuppression and addition of medications with anti-inflammatory or anti-fibrotic mechanisms distinct from tacrolimus: azithromycin, a macrolide antibiotic that in the transplant setting functioned primarily as an anti-inflammatory agent, had been shown in several trials to stabilize FEV1 decline in a subset of BOS patients, particularly those with neutrophilic airway inflammation detectable in bronchoalveolar lavage. Montelukast, a leukotriene receptor antagonist, was sometimes added given evidence of modest benefit in some patients. The transplant team was also discussing whether converting Carlos from tacrolimus to sirolimus — an mTOR inhibitor with anti-fibrotic properties through suppression of platelet-derived growth factor signaling — was appropriate; sirolimus had a different immunosuppressive mechanism and additionally suppressed fibroblast proliferation in ways that tacrolimus did not.
Second, close monitoring. BOS was graded by the decline in FEV1 from best post-transplant value: Grade 0.5 (potential BOS) was a 10 to 19 percent decline; Grade 1 was a 20 to 34 percent decline; Grade 2 was a 35 to 49 percent decline; Grade 3 was 50 percent or greater. Carlos was at Grade 1 — a decline of approximately 25 percent from his best value of 2.8 liters. Early-stage detection and intervention offered the best opportunity to stabilize the process. Waiting until Grade 2 or 3 reduced treatment options substantially.
“Lo que vamos a hacer tiene dos partes,” Patricia said. “Primero, vamos a agregar azitromicina — no como antibiótico, sino como antiinflamatorio que ha mostrado frenar este proceso en muchos pacientes. Y vamos a considerar cambiar el tacrolimus a otro medicamento llamado sirolimus, que tiene un mecanismo diferente y que también tiene propiedades antifibrosis. Segundo, vamos a monitorear de cerca — espirom&etría cada seis semanas en lugar de cada seis meses, para saber si la intervención está funcionando o si necesitamos ajustar. Haber detectado esto ahora, con una caída del 25 por ciento, es el momento en que podemos intervenir de manera efectiva. Usted ha hecho todo bien durante dos años y medio. Eso le da la mejor posición posible para enfrentar esto.” (What we are going to do has two parts. First, we are going to add azithromycin — not as an antibiotic, but as an anti-inflammatory that has shown to slow this process in many patients. And we are going to consider changing tacrolimus to another medication called sirolimus, which has a different mechanism and also has anti-fibrotic properties. Second, we are going to monitor closely — spirometry every six weeks instead of every six months, to know whether the intervention is working or whether we need to adjust. Having detected this now, with a 25 percent decline, is the moment when we can intervene effectively. You have done everything right for two and a half years. That puts you in the best possible position to face this.)
Carlos looked at the printout. “O sea, el tacrolimus protegió los pulmones del rechazo. Y ahora agregan medicamentos para protegerlos de este otro proceso.” (So the tacrolimus protected the lungs from rejection. And now you are adding medications to protect them from this other process.)
“Exactamente,” Patricia said. “Dos procesos diferentes, dos mecanismos de protección diferentes. El primero está cubierto. El segundo ahora también lo estará.” (Exactly. Two different processes, two different protection mechanisms. The first is covered. The second will now be covered too.)
Carlos agreed to the azithromycin and returned two weeks later for the sirolimus conversion discussion with the full transplant team.
The discipline that connects all three scenarios
Juan Morales waiting in the evaluation clinic and feeling that every week of testing is a week the transplant is not moving. Maria Elena Ortiz-Vargas in the step-down unit, more short of breath than before surgery, looking at the extra oxygen tubing as evidence of something gone wrong. Carlos Mendoza-Ríos watching his spirometry number drop from 2.8 to 2.1 on perfect immunosuppression, trying to reconcile a number that does not fit the model he has faithfully operated within for two and a half years. Each misunderstanding is structurally complete — the patient’s conclusion follows logically from the information they have. And each is wrong in a way that matters enormously for what the patient does next.
Juan’s belief that the evaluation gate must close before the waitlist opens matters because, if uncorrected, it produces a patient who delays or resists evaluation components — skips rehabilitation sessions, deprioritizes nutritional appointments — because those components feel like administrative requirements rather than the specific pre-surgical interventions that will determine whether he survives the surgery that the waitlist is working to deliver. The Lung Allocation Score correction matters not just as information but as a reframe: the evaluation is not the obstacle to the list — the evaluation is the work that determines how well the lung, when it comes, will be received.
Maria Elena’s belief that more oxygen on day three means something went wrong matters because it generates acute distress, potential refusal of care, and family escalation at the exact moment when the clinical team needs the patient and family engaged in close monitoring. The distinction between primary graft dysfunction and rejection — different mechanisms, different time courses, different treatments — is not a technical detail for the nurse; it is the explanation that transforms the patient from a frightened observer of a failure into an informed participant in a recovery that the nurse can make visible through the P/F ratio trajectory.
Carlos’s belief that perfect tacrolimus adherence should protect against FEV1 decline matters because it generates the most damaging possible inference: that either he has been doing something wrong, or the doctors are wrong about the disease, or the transplant that he worked so hard to survive is failing in a way that cannot be fixed. The CLAD/BOS explanation matters not just as information but as a restoration of agency: the tacrolimus did exactly what it was supposed to do for two and a half years; this is a different process that requires different treatment; we detected it early; we have tools to address it; you are in the best possible position to face this because you have been doing everything right.
In each case, the lung transplant nurse working in Spanish is doing something that goes beyond clinical education: they are rebuilding the patient’s accurate model of what is happening in their body and what that means for what they should do next. The patient who understands what the LAS score means stays in rehabilitation. The patient who understands what PGD is and what the P/F ratio trajectory means remains engaged in monitoring. The patient who understands that BOS is a different process from rejection — and that adherence was not in vain — arrives at the azithromycin discussion prepared to add to an approach that has worked rather than replace one that has failed. The Spanish-language explanation is not a translation of the clinical note; it is the means by which the biology becomes intelligible to the person whose lungs it is happening in.
Key phrases for lung transplant nurses working with Spanish-speaking patients:
- On the evaluation timeline: “La evaluación y la lista de espera ocurren al mismo tiempo — no son pasos que van uno después del otro. Su puntaje de asignación pulmonar ya existe y ya refleja su situación actual. Lo que hacemos en la evaluación es preparar su cuerpo para la cirugía mientras la lista funciona en paralelo.” (The evaluation and the waitlist happen at the same time — they are not steps that go one after the other. Your lung allocation score already exists and already reflects your current situation. What we do in the evaluation is prepare your body for surgery while the list works in parallel.)
- On primary graft dysfunction: “Lo que está ocurriendo no es rechazo. Es disfunción primaria del injerto — una reacción inflamatoria al período en que los pulmones estuvieron sin circulación durante la cirugía. Ocurre en las primeras 72 horas y se resuelve en la mayoría de los pacientes en tres a cuatro días. El rechazo es un proceso completamente diferente que empieza después del día 5.” (What is happening is not rejection. It is primary graft dysfunction — an inflammatory reaction to the period when the lungs were without circulation during surgery. It occurs in the first 72 hours and resolves in most patients in three to four days. Rejection is a completely different process that starts after day 5.)
- On CLAD/BOS for the adherent patient: “El tacrolimus hizo exactamente lo que debía hacer: prevenir el rechazo celular agudo. Usted hizo todo bien. Lo que está ocurriendo ahora es un proceso diferente en los bronquiolos pequeños que el tacrolimus no está diseñado para prevenir. Ahora agregamos medicamentos con un mecanismo diferente para ese proceso específico.” (Tacrolimus did exactly what it was supposed to do: prevent acute cellular rejection. You did everything right. What is happening now is a different process in the small bronchioles that tacrolimus is not designed to prevent. Now we add medications with a different mechanism for that specific process.)
- On immunosuppression permanence: “El tacrolimus no se puede reducir porque el trasplante parece estar yendo bien — el tacrolimus es lo que hace posible que esté yendo bien. Los pulmones son el órgano trasplantado que más necesita esta protección, porque están en contacto constante con el ambiente externo. Esa protección no se reduce con el tiempo.” (Tacrolimus cannot be reduced because the transplant seems to be going well — tacrolimus is what makes it possible for it to be going well. The lungs are the transplanted organ that most needs this protection, because they are in constant contact with the external environment. That protection does not decrease with time.)